Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect.
about
Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectivesTailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunctionImpact of a Telehealth Program With Voice Recognition Technology in Patients With Chronic Heart Failure: Feasibility StudyAssociation between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications.Association of mineralocorticoid receptor antagonist use and in-hospital outcomes in patients with acute heart failure.
P2860
Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Spot urine sodium excretion as ...... re: the spironolactone effect.
@en
type
label
Spot urine sodium excretion as ...... re: the spironolactone effect.
@en
prefLabel
Spot urine sodium excretion as ...... re: the spironolactone effect.
@en
P2093
P2860
P50
P1476
Spot urine sodium excretion as ...... ure: the spironolactone effect
@en
P2093
David Kénizou
Faiez Zannad
Javed Butler
Patrick Rossignol
Pedro Bettencourt Medeiros
P2860
P2888
P304
P356
10.1007/S00392-015-0945-X
P577
2015-11-28T00:00:00Z